Study identifies cognitive benefits of ketamine in patients with treatment-resistant depression

By The Conversation | December 8, 2022

Which fac­tors deter­mine what we believe about our world, our­selves, our past, and our future? Cog­ni­tive neu­ro­science sug­gests that our beliefs are depen­dent on brain activ­i­ty, specif­i­cal­ly on the way our brains process sen­so­ry infor­ma­tion in order to make sense of our envi­ron­ment. These beliefs (defined as prob­a­bil­i­ty esti­mates) are cen­tral to our brain’s predictive…

Read More

Otsuka and Virtual Reality start-up Jolly Good sign $43M deal to promote Social Skills Training (SST) therapies, helping schizophrenia patients first

By SharpBrains | February 2, 2022

Otsu­ka signs on Jol­ly Good for $43M men­tal health VR deal (Fierce Biotech): The duo will build out software—hosted on Jol­ly Good’s VR gog­gles and con­nect­ed tablet devices, and backed by Otsuka’s exper­tise in devel­op­ing neu­ro­log­i­cal therapeutics—that takes a social skills train­ing (SST) approach to treat­ing men­tal ill­ness. SST is a behav­ioral ther­a­py in which…

Read More

Debunking four myths about decision-making capacity to keep Britney Spears and others safe

By The Conversation | August 9, 2021

Brit­ney Spears’ impas­sioned remarks in court have raised many ques­tions about con­ser­va­tor­ships, includ­ing when they’re nec­es­sary and whether they effec­tive­ly pro­tect someone’s best inter­ests. When one los­es the capac­i­ty to make deci­sions for one­self the court appoints a guardian, or con­ser­va­tor, to make those deci­sions. Appoint­ing some­one to make deci­sions about per­son­al and finan­cial matters…

Read More

Update: A life of cognitive and physical exercise helps you stay sharp in your 70s and beyond

By SharpBrains | September 25, 2020

Wel­come to a new edi­tion of Sharp­Brains’ e‑newsletter, fea­tur­ing 13 fas­ci­nat­ing brain research find­ings, use­ful resources–and a brain teas­er to test your atten­tion skills. #1. Good news of the month: Elders today are in sig­nif­i­cant­ly bet­ter shape–physically and cognitively–than three decades ago #2. A dis­tinc­tion WITH a dif­fer­ence: Actu­al, sus­tained practice–not mere knowledge–is need­ed to…

Read More

Click Therapeutics and Boehringer Ingelheim partner to develop and market a digital therapeutic to treat schizophrenia

By SharpBrains | September 21, 2020

Boehringer Ingel­heim, Click Ther­a­peu­tics ink $500M+ dig­i­tal ther­a­peu­tics devel­op­ment, com­mer­cial­iza­tion deal (Mobi­Health­News): Inter­na­tion­al phar­ma Boehringer Ingel­heim and pre­scrip­tion dig­i­tal ther­a­peu­tics com­pa­ny Click Ther­a­peu­tics have inked a $500 mil­lion-plus deal to joint­ly devel­op and com­mer­cial­ize a dig­i­tal treat­ment for patients with schizophrenia.

Read More

The way we approach Mental Health today is broken beyond repair. The question is, what comes next, and how fast can we get there?

By SharpBrains | June 3, 2020

The hid­den links between men­tal dis­or­ders (Nature): In 2018, psy­chi­a­trist Oleguer Plana-Ripoll was wrestling with a puz­zling fact about men­tal dis­or­ders. He knew that many indi­vid­u­als have mul­ti­ple con­di­tions — anx­i­ety and depres­sion, say, or schiz­o­phre­nia and bipo­lar dis­or­der. He want­ed to know how com­mon it was to have more than one diag­no­sis, so he…

Read More